종양 절제 시장 : 기술별, 치료별, 용도별 - 세계 기회 분석 및 산업 예측(2022-2032년)

The tumor ablation market was valued at $1,413.85 million in 2022 and is estimated to reach $5,032.44 million by 2032, exhibiting a CAGR of 13.5% from 2022 to 2032. Tumor ablation techniques, also referred to as minimally invasive technology, are used to treat tumors of kidney, bones, liver, and lungs. They use heat to target a specific tumor cell. It is a needle-like device with a heat-generating component that leads to cellular necrosis of targeted tumor cell. It is performed in-vivo, without taking tumors out of the body.

The method eliminates benign tumors by inserting a probe and heating it to 100 degrees Celsius under precise computer tomography. There are different methods available for tumor ablation such as microwave ablation, radiofrequency ablation, cryoablation, and others that can be used for disease diagnosis and treatment. Repeated use of ablation methods helps reduce patient's pain and risk while increasing accuracy and treating a broader type of cancer.

The growth of the global tumor ablation market is majorly driven by increase in prevalence of cancer, and high adoption of the tumor ablation-based treatments. Moreover, adoption and emergence of technologically advanced tumor ablation techniques including the advent of thermal and laser ablation, irreversible electroporation, and high-intensity focused ultrasound (HIFU) are the factors that influence the market growth. Increase in safety regarding use of ablation techniques, increase in geriatric population, and increase in public-private initiatives & funding to support ongoing research activities related to tumor ablation drive the market growth.

Cancer, a devastating and potentially life-threatening disease, has been steadily increasing in incidence across the globe. For instance, according to the National Center for Health Statistics. In 2023, 1,958,310 new cancer cases and 609,820 cancer deaths are projected to occur in the U.S. This surge can be attributed to several factors, including an aging population, lifestyle changes, and improved diagnostics that enable earlier detection of tumors. Tumor ablation techniques have gained significant prominence in the field of oncology due to their ability to destroy cancerous tissue without the need for extensive surgeries.

Additionally, tumor ablation techniques are often utilized for patients who are not candidates for surgery or as a palliative option to relieve symptoms in advanced cancer cases. The increasing prevalence of cancer not only drives the demand for tumor ablation procedures but also stimulates ongoing research and development efforts to enhance the efficacy and accessibility of these treatments. This, in turn, fosters innovation in the tumor ablation market, leading to the introduction of advanced technologies and improved devices, which further boosts market growth. Thus, the rise in prevalence of cancer is expected to drive the growth of the market.

Furthermore, the high adoption of tumor ablation-based treatments has emerged as a major driving factor for the growth of the tumor ablation market. Tumor ablation techniques, such as radiofrequency ablation (RFA), microwave ablation, and cryoablation, have gained significant popularity in recent years due to their effectiveness in treating various types of tumors, including liver, lung, kidney, and bone tumors. Tumor ablation procedures offer several distinct advantages over traditional surgical methods. They are minimally invasive, which means they involve smaller incisions or, in some cases, no incisions at all. This results in shorter recovery times, reduced hospital stays, and lower post-operative complications, making them more attractive options for both patients and healthcare providers.

For instance, according to a 2021 report by the National Library of Medicine, it was reported that percutaneous ablation is safe and nearly as efficacious as surgery, usually requiring a lower cost and shorter hospital stay for single hepatocellular carcinoma. In addition, advancements in technology and imaging have greatly improved the precision and accuracy of tumor ablation procedures. Real-time imaging guidance, such as ultrasound, CT scans, or MRI, allows medical professionals to precisely target and monitor the tumor during the ablation process, ensuring thorough destruction of the cancerous tissue while sparing healthy surrounding organs and tissues. Thus, the surge in adoption of tumor ablation-based treatments is expected to significantly contribute to the growth of the market.

However, side-effects associated with tumor ablation treatment might restrain the growth of the market. Moreover, a rise in research and development activities for tumor ablation is expected to present significant growth opportunities to the market. The tumor ablation market is segmented on the basis of technology, treatment, application, and region. By technology, the market is classified into radiofrequency ablation, microwave ablation, cryo-ablation, irreversible electroporation ablation, and others. By treatment, it is classified into surgical ablation, laparoscopic ablation, and percutaneous ablation. By application, it is classified into kidney cancer, liver cancer, breast cancer, lung cancer, prostate cancer and bone cancer. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).Major key players that operate in the global tumor ablation market are Medtronic plc, Boston Scientific Corporation, Smith and Nephew PLC, Integra LifeSciences Holding Corporation, AngioDynamics Inc, HealthTronics, Inc, Bioventus (Misonix Inc), Johnson and Johnson, ConMed Corporation and Olympus Corporation.

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the tumor ablation market analysis from 2022 to 2032 to identify the prevailing tumor ablation market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the tumor ablation market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global tumor ablation market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

• Quarterly Update and* (only available with a corporate license, on listed price)
• 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
• Free Upcoming Version on the Purchase of Five and Enterprise User License.
• 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
• 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
• Free data Pack on the Five and Enterprise User License. (Excel version of the report)
• Free Updated report if the report is 6-12 months old or older.
• 24-hour priority response*
• Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

• Market share analysis of players by products/segments
• New Product Development/ Product Matrix of Key Players
• Additional company profiles with specific to client's interest
• Additional country or region analysis- market size and forecast
• Average Selling Price Analysis / Price Point Analysis
• Expanded list for Company Profiles
• Historic market data
• SWOT Analysis

Key Market Segments

By Technology

• Radiofrequency Ablation
• Microwave Ablation
• Cryoablation
• Irreversible Electroporation Ablation
• Other Ablation Technologies

By Treatment

• Surgical Ablation
• Laparoscopic Ablation
• Percutaneous Ablation

By Application

• Kidney Cancer
• Liver Cancer
• Breast Cancer
• Lung Cancer
• Prostate Cancer
• Bone Cancer

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • South Korea
  • Rest of Asia-Pacific
• LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

Key Market Players:

• Olympus Corporation
• AngioDynamics, Inc.
• Bioventus LLC
• Johnson & Johnson
• Medtronic plc
• ConMed Corporation
• Smith & Nephew plc
• Integra LifeSciences Holdings Corporation
• HealthTronics, Inc.
• Boston Scientific Corporation

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

• 1.1. Report description
• 1.2. Key market segments
• 1.3. Key benefits to the stakeholders
• 1.4. Research methodology
  • 1.4.1. Primary research
  • 1.4.2. Secondary research
  • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

• 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

• 3.1. Market definition and scope
• 3.2. Key findings
  • 3.2.1. Top impacting factors
  • 3.2.2. Top investment pockets
• 3.3. Porter's five forces analysis
  • 3.3.1. Low bargaining power of suppliers
  • 3.3.2. Low threat of new entrants
  • 3.3.3. Low threat of substitutes
  • 3.3.4. Low intensity of rivalry
  • 3.3.5. Low bargaining power of buyers
• 3.4. Market dynamics
  • 3.4.1. Drivers
    • 3.4.1.1. Increase in prevalence of cancers across the globe.
    • 3.4.1.2. Increase in demand for minimally invasive tumor ablation techniques.
  • 3.4.2. Restraints
    • 3.4.2.1. Side-effects associated with tumor ablation treatment.
  • 3.4.3. Opportunities
    • 3.4.3.1. Rise in research and development activities for tumor ablation.

CHAPTER 4: TUMOR ABLATION MARKET, BY TECHNOLOGY

• 4.1. Overview
  • 4.1.1. Market size and forecast
• 4.2. Radiofrequency Ablation
  • 4.2.1. Key market trends, growth factors and opportunities
  • 4.2.2. Market size and forecast, by region
  • 4.2.3. Market share analysis by country
• 4.3. Microwave Ablation
  • 4.3.1. Key market trends, growth factors and opportunities
  • 4.3.2. Market size and forecast, by region
  • 4.3.3. Market share analysis by country
• 4.4. Cryoablation
  • 4.4.1. Key market trends, growth factors and opportunities
  • 4.4.2. Market size and forecast, by region
  • 4.4.3. Market share analysis by country
• 4.5. Irreversible Electroporation Ablation
  • 4.5.1. Key market trends, growth factors and opportunities
  • 4.5.2. Market size and forecast, by region
  • 4.5.3. Market share analysis by country
• 4.6. Other Ablation Technologies
  • 4.6.1. Key market trends, growth factors and opportunities
  • 4.6.2. Market size and forecast, by region
  • 4.6.3. Market share analysis by country

CHAPTER 5: TUMOR ABLATION MARKET, BY TREATMENT

• 5.1. Overview
  • 5.1.1. Market size and forecast
• 5.2. Surgical Ablation
  • 5.2.1. Key market trends, growth factors and opportunities
  • 5.2.2. Market size and forecast, by region
  • 5.2.3. Market share analysis by country
• 5.3. Laparoscopic Ablation
  • 5.3.1. Key market trends, growth factors and opportunities
  • 5.3.2. Market size and forecast, by region
  • 5.3.3. Market share analysis by country
• 5.4. Percutaneous Ablation
  • 5.4.1. Key market trends, growth factors and opportunities
  • 5.4.2. Market size and forecast, by region
  • 5.4.3. Market share analysis by country

CHAPTER 6: TUMOR ABLATION MARKET, BY APPLICATION

• 6.1. Overview
  • 6.1.1. Market size and forecast
• 6.2. Kidney Cancer
  • 6.2.1. Key market trends, growth factors and opportunities
  • 6.2.2. Market size and forecast, by region
  • 6.2.3. Market share analysis by country
• 6.3. Liver Cancer
  • 6.3.1. Key market trends, growth factors and opportunities
  • 6.3.2. Market size and forecast, by region
  • 6.3.3. Market share analysis by country
• 6.4. Breast Cancer
  • 6.4.1. Key market trends, growth factors and opportunities
  • 6.4.2. Market size and forecast, by region
  • 6.4.3. Market share analysis by country
• 6.5. Lung Cancer
  • 6.5.1. Key market trends, growth factors and opportunities
  • 6.5.2. Market size and forecast, by region
  • 6.5.3. Market share analysis by country
• 6.6. Prostate Cancer
  • 6.6.1. Key market trends, growth factors and opportunities
  • 6.6.2. Market size and forecast, by region
  • 6.6.3. Market share analysis by country
• 6.7. Bone Cancer
  • 6.7.1. Key market trends, growth factors and opportunities
  • 6.7.2. Market size and forecast, by region
  • 6.7.3. Market share analysis by country

CHAPTER 7: TUMOR ABLATION MARKET, BY REGION

• 7.1. Overview
  • 7.1.1. Market size and forecast By Region
• 7.2. North America
  • 7.2.1. Key market trends, growth factors and opportunities
  • 7.2.2. Market size and forecast, by Technology
  • 7.2.3. Market size and forecast, by Treatment
  • 7.2.4. Market size and forecast, by Application
  • 7.2.5. Market size and forecast, by country
    • 7.2.5.1. U.S.
    • 7.2.5.1.1. Market size and forecast, by Technology
    • 7.2.5.1.2. Market size and forecast, by Treatment
    • 7.2.5.1.3. Market size and forecast, by Application
    • 7.2.5.2. Canada
    • 7.2.5.2.1. Market size and forecast, by Technology
    • 7.2.5.2.2. Market size and forecast, by Treatment
    • 7.2.5.2.3. Market size and forecast, by Application
    • 7.2.5.3. Mexico
    • 7.2.5.3.1. Market size and forecast, by Technology
    • 7.2.5.3.2. Market size and forecast, by Treatment
    • 7.2.5.3.3. Market size and forecast, by Application
• 7.3. Europe
  • 7.3.1. Key market trends, growth factors and opportunities
  • 7.3.2. Market size and forecast, by Technology
  • 7.3.3. Market size and forecast, by Treatment
  • 7.3.4. Market size and forecast, by Application
  • 7.3.5. Market size and forecast, by country
    • 7.3.5.1. Germany
    • 7.3.5.1.1. Market size and forecast, by Technology
    • 7.3.5.1.2. Market size and forecast, by Treatment
    • 7.3.5.1.3. Market size and forecast, by Application
    • 7.3.5.2. France
    • 7.3.5.2.1. Market size and forecast, by Technology
    • 7.3.5.2.2. Market size and forecast, by Treatment
    • 7.3.5.2.3. Market size and forecast, by Application
    • 7.3.5.3. UK
    • 7.3.5.3.1. Market size and forecast, by Technology
    • 7.3.5.3.2. Market size and forecast, by Treatment
    • 7.3.5.3.3. Market size and forecast, by Application
    • 7.3.5.4. Italy
    • 7.3.5.4.1. Market size and forecast, by Technology
    • 7.3.5.4.2. Market size and forecast, by Treatment
    • 7.3.5.4.3. Market size and forecast, by Application
    • 7.3.5.5. Spain
    • 7.3.5.5.1. Market size and forecast, by Technology
    • 7.3.5.5.2. Market size and forecast, by Treatment
    • 7.3.5.5.3. Market size and forecast, by Application
    • 7.3.5.6. Rest of Europe
    • 7.3.5.6.1. Market size and forecast, by Technology
    • 7.3.5.6.2. Market size and forecast, by Treatment
    • 7.3.5.6.3. Market size and forecast, by Application
• 7.4. Asia-Pacific
  • 7.4.1. Key market trends, growth factors and opportunities
  • 7.4.2. Market size and forecast, by Technology
  • 7.4.3. Market size and forecast, by Treatment
  • 7.4.4. Market size and forecast, by Application
  • 7.4.5. Market size and forecast, by country
    • 7.4.5.1. Japan
    • 7.4.5.1.1. Market size and forecast, by Technology
    • 7.4.5.1.2. Market size and forecast, by Treatment
    • 7.4.5.1.3. Market size and forecast, by Application
    • 7.4.5.2. China
    • 7.4.5.2.1. Market size and forecast, by Technology
    • 7.4.5.2.2. Market size and forecast, by Treatment
    • 7.4.5.2.3. Market size and forecast, by Application
    • 7.4.5.3. Australia
    • 7.4.5.3.1. Market size and forecast, by Technology
    • 7.4.5.3.2. Market size and forecast, by Treatment
    • 7.4.5.3.3. Market size and forecast, by Application
    • 7.4.5.4. India
    • 7.4.5.4.1. Market size and forecast, by Technology
    • 7.4.5.4.2. Market size and forecast, by Treatment
    • 7.4.5.4.3. Market size and forecast, by Application
    • 7.4.5.5. South Korea
    • 7.4.5.5.1. Market size and forecast, by Technology
    • 7.4.5.5.2. Market size and forecast, by Treatment
    • 7.4.5.5.3. Market size and forecast, by Application
    • 7.4.5.6. Rest of Asia-Pacific
    • 7.4.5.6.1. Market size and forecast, by Technology
    • 7.4.5.6.2. Market size and forecast, by Treatment
    • 7.4.5.6.3. Market size and forecast, by Application
• 7.5. LAMEA
  • 7.5.1. Key market trends, growth factors and opportunities
  • 7.5.2. Market size and forecast, by Technology
  • 7.5.3. Market size and forecast, by Treatment
  • 7.5.4. Market size and forecast, by Application
  • 7.5.5. Market size and forecast, by country
    • 7.5.5.1. Brazil
    • 7.5.5.1.1. Market size and forecast, by Technology
    • 7.5.5.1.2. Market size and forecast, by Treatment
    • 7.5.5.1.3. Market size and forecast, by Application
    • 7.5.5.2. Saudi Arabia
    • 7.5.5.2.1. Market size and forecast, by Technology
    • 7.5.5.2.2. Market size and forecast, by Treatment
    • 7.5.5.2.3. Market size and forecast, by Application
    • 7.5.5.3. South Africa
    • 7.5.5.3.1. Market size and forecast, by Technology
    • 7.5.5.3.2. Market size and forecast, by Treatment
    • 7.5.5.3.3. Market size and forecast, by Application
    • 7.5.5.4. Rest of LAMEA
    • 7.5.5.4.1. Market size and forecast, by Technology
    • 7.5.5.4.2. Market size and forecast, by Treatment
    • 7.5.5.4.3. Market size and forecast, by Application

CHAPTER 8: COMPETITIVE LANDSCAPE

• 8.1. Introduction
• 8.2. Top winning strategies
• 8.3. Product mapping of top 10 player
• 8.4. Competitive dashboard
• 8.5. Competitive heatmap
• 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

• 9.1. Medtronic plc
  • 9.1.1. Company overview
  • 9.1.2. Key executives
  • 9.1.3. Company snapshot
  • 9.1.4. Operating business segments
  • 9.1.5. Product portfolio
  • 9.1.6. Business performance
• 9.2. Boston Scientific Corporation
  • 9.2.1. Company overview
  • 9.2.2. Key executives
  • 9.2.3. Company snapshot
  • 9.2.4. Operating business segments
  • 9.2.5. Product portfolio
  • 9.2.6. Business performance
• 9.3. Smith & Nephew plc
  • 9.3.1. Company overview
  • 9.3.2. Key executives
  • 9.3.3. Company snapshot
  • 9.3.4. Operating business segments
  • 9.3.5. Product portfolio
  • 9.3.6. Business performance
• 9.4. AngioDynamics, Inc.
  • 9.4.1. Company overview
  • 9.4.2. Key executives
  • 9.4.3. Company snapshot
  • 9.4.4. Operating business segments
  • 9.4.5. Product portfolio
  • 9.4.6. Business performance
  • 9.4.7. Key strategic moves and developments
• 9.5. HealthTronics, Inc.
  • 9.5.1. Company overview
  • 9.5.2. Key executives
  • 9.5.3. Company snapshot
  • 9.5.4. Operating business segments
  • 9.5.5. Product portfolio
• 9.6. Bioventus LLC
  • 9.6.1. Company overview
  • 9.6.2. Key executives
  • 9.6.3. Company snapshot
  • 9.6.4. Operating business segments
  • 9.6.5. Product portfolio
  • 9.6.6. Business performance
  • 9.6.7. Key strategic moves and developments
• 9.7. Johnson & Johnson
  • 9.7.1. Company overview
  • 9.7.2. Key executives
  • 9.7.3. Company snapshot
  • 9.7.4. Operating business segments
  • 9.7.5. Product portfolio
  • 9.7.6. Business performance
  • 9.7.7. Key strategic moves and developments
• 9.8. ConMed Corporation
  • 9.8.1. Company overview
  • 9.8.2. Key executives
  • 9.8.3. Company snapshot
  • 9.8.4. Operating business segments
  • 9.8.5. Product portfolio
  • 9.8.6. Business performance
• 9.9. Olympus Corporation
  • 9.9.1. Company overview
  • 9.9.2. Key executives
  • 9.9.3. Company snapshot
  • 9.9.4. Operating business segments
  • 9.9.5. Product portfolio
  • 9.9.6. Business performance
• 9.10. Integra LifeSciences Holdings Corporation
  • 9.10.1. Company overview
  • 9.10.2. Key executives
  • 9.10.3. Company snapshot
  • 9.10.4. Operating business segments
  • 9.10.5. Product portfolio
  • 9.10.6. Business performance
  • 9.10.7. Key strategic moves and developments